Dean A. Wetherbee 5/14/26 Dean A. Wetherbee 5/14/26 ASGCT and Orphan Therapeutics Accelerator Launch CGTxchange -- A First-of-Its-Kind Marketplace to Reactivate Promising Shelved Cell and Gene Therapy Programs Read More Dean A. Wetherbee 5/11/26 Dean A. Wetherbee 5/11/26 AGC Biologics Joins Orphan Therapeutics Accelerator’s Clinical Development Network as a Manufacturing Partner to Advance Cell and Gene Therapies for Ultra-Rare Diseases Read More Dean A. Wetherbee 2/25/26 Dean A. Wetherbee 2/25/26 P4ML Becomes Founding Member of Orphan Therapeutics Accelerator (OTXL) to Support Broader Global Access to Ultra-Rare Disease Treatments Read More Dean A. Wetherbee 1/7/26 Dean A. Wetherbee 1/7/26 ASGCT and Orphan Therapeutics Accelerator Launch CGTxchange - A First-of-Its-Kind Marketplace to Reactivate Promising Shelved Cell and Gene Therapy Programs Read More Dean A. Wetherbee 12/15/25 Dean A. Wetherbee 12/15/25 Fondazione Telethon and Orphan Therapeutics Accelerator Sign Memorandum of Understanding to Pioneer Nonprofit Commercial Access Model for Ultra-Rare Disease Gene Therapy in the US Read More Dean A. Wetherbee 8/12/25 Dean A. Wetherbee 8/12/25 Orphan Therapeutics Accelerator Launches Orphan Therapies, a Non-Profit Biotech Dedicated to Commercializing Ultra-Rare Disease Treatments Read More Dean A. Wetherbee 5/14/25 Dean A. Wetherbee 5/14/25 Viralgen Joins Orphan Therapeutics Accelerator Clinical Development Network as a Manufacturing Partner to Advance Rare Disease Therapies Read More Dean A. Wetherbee 4/23/25 Dean A. Wetherbee 4/23/25 Orphan Therapeutics Accelerator Announces Foundational Partnerships Read More
Dean A. Wetherbee 5/14/26 Dean A. Wetherbee 5/14/26 ASGCT and Orphan Therapeutics Accelerator Launch CGTxchange -- A First-of-Its-Kind Marketplace to Reactivate Promising Shelved Cell and Gene Therapy Programs Read More
Dean A. Wetherbee 5/11/26 Dean A. Wetherbee 5/11/26 AGC Biologics Joins Orphan Therapeutics Accelerator’s Clinical Development Network as a Manufacturing Partner to Advance Cell and Gene Therapies for Ultra-Rare Diseases Read More
Dean A. Wetherbee 2/25/26 Dean A. Wetherbee 2/25/26 P4ML Becomes Founding Member of Orphan Therapeutics Accelerator (OTXL) to Support Broader Global Access to Ultra-Rare Disease Treatments Read More
Dean A. Wetherbee 1/7/26 Dean A. Wetherbee 1/7/26 ASGCT and Orphan Therapeutics Accelerator Launch CGTxchange - A First-of-Its-Kind Marketplace to Reactivate Promising Shelved Cell and Gene Therapy Programs Read More
Dean A. Wetherbee 12/15/25 Dean A. Wetherbee 12/15/25 Fondazione Telethon and Orphan Therapeutics Accelerator Sign Memorandum of Understanding to Pioneer Nonprofit Commercial Access Model for Ultra-Rare Disease Gene Therapy in the US Read More
Dean A. Wetherbee 8/12/25 Dean A. Wetherbee 8/12/25 Orphan Therapeutics Accelerator Launches Orphan Therapies, a Non-Profit Biotech Dedicated to Commercializing Ultra-Rare Disease Treatments Read More
Dean A. Wetherbee 5/14/25 Dean A. Wetherbee 5/14/25 Viralgen Joins Orphan Therapeutics Accelerator Clinical Development Network as a Manufacturing Partner to Advance Rare Disease Therapies Read More
Dean A. Wetherbee 4/23/25 Dean A. Wetherbee 4/23/25 Orphan Therapeutics Accelerator Announces Foundational Partnerships Read More
